Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

60;During 2009, within Generics, Mylan recognized $28.5 million of incremental other revenue resulting from the cancellation of product development agreements for which the revenue had been previously deferred.  There was no such revenue recognized during the current year.  

A tabular summary of the Company's revenues for the years ended December 31, 2010, and 2009, is included at the end of this release.

Generics third party net sales were $4.98 billion in 2010, compared to $4.61 billion in prior year.

Third party net sales from North America were $2.36 billion in 2010, compared to $2.09 billion for the prior year, representing an increase of $265.0 million, or 12.6%. The increase was driven by increased volume, new product launches and incremental revenue from the Bioniche Pharma acquisition, partially offset by unfavorable pricing on certain existing products, including divalproex sodium extended-release (divalproex ER) tablets, the generic version of Abbott Laboratories' Depakote® ER, for which Mylan had exclusivity for a portion of 2009.

New products launched in the US and Canada contributed sales of $158.6 million, over half of which consisted of valacyclovir hydrochloride tablets, the generic version of GlaxoSmithKline's Valtrex®, and minocycline hydrochloride extended release tablets, the generic version of Medicis Pharmaceutical Corporation's Solodyn® ER.  The Company's ability to continue to be a stable and reliable source of supply to the market resulted in the favorable volume on its existing product base.

Third party net sales from EMEA were $1.55 billion for 2010, compared to $1.64 billion for the prior year, a decrease of $90.8 million, or 5.5%. However, translating current year third party net revenues from EMEA at prior year exchange rates would result in a decrease excluding the effect of foreign currency translations of approximately $24 million, or 1%.  This decrease was m
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
(Date:6/18/2013)... (Monday, June 17, 2013) A million electric cars could ... the decade with the help of research by the United ... University of Waterloo. , Professor Zhongwei Chen is part of ... to develop non-precious materials to replace the expensive platinum catalysts ... the adoption of fuel cells in vehicles is the cost ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
(Date:6/18/2013)... FL (PRWEB) June 18, 2013 The human ... the skin as an important human body part. Similar to ... for in order to function, repair and grow. Recent reports ... vitamins and supplements, is just as important as other life ... supplements to aid in skin cell reproduction, increase the appearance ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2
... LA JOLLA, Calif., Feb. 11 Cordex Pharma, Inc. ... a Medical Advisory Board to provide clinical guidance for ... of heart failure.The Medical Advisory Board will play an ... the planned CDP-1050 Phase 2 clinical trial and assist ...
... GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an ... for diseases caused by HIV-1 (Human Immunodeficiency Virus) ... McNally, Ph.D., Chief Executive Officer and President, presented ... CEO & Investor Conference 2009, held at the ...
... AMSTERDAM, The Netherlands, February 11, Agendia, a world ... of Alan B. Carter as the company,s new ... "As we continue to grow as ... primary aims," commented Dr. Bernhard Sixt, Ph.D., President ...
Cached Biology Technology:Cordex Pharma Forms Heart Failure Medical Advisory Board 2Cordex Pharma Forms Heart Failure Medical Advisory Board 3Cordex Pharma Forms Heart Failure Medical Advisory Board 4Cordex Pharma Forms Heart Failure Medical Advisory Board 5GeoVax Update Provided at the BIO CEO & Investor Conference 2009 2GeoVax Update Provided at the BIO CEO & Investor Conference 2009 3GeoVax Update Provided at the BIO CEO & Investor Conference 2009 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 5Agendia Appoints VP of Business Development 2
(Date:6/19/2013)... The PETA International Science Consortium (PISC) is extremely ... of Appeal has upheld a decision that requires ... study in rats. The study will use approximately ... unborn pups to the substance dipropylene glycol methyl ... the European Community,s Regulation on the Registration, Evaluation, ...
(Date:6/19/2013)... University of Pittsburgh has developed antibacterial compounds, derived ... be potential treatments for drug-resistant bacterial infections and ... are quite small, making them inexpensive and easy ... June 2013 issue of the journal Antimicrobial ... many probable applications will likely be the chronic ...
(Date:6/19/2013)... new variety of canary seeds bred specifically for human ... ideal for people with celiac disease (CD), scientists have ... of Agricultural and Food Chemistry . , Joyce ... 3 million people in the United States alone have ... wheat, barley, rye and other grains that contain gluten-related ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... Ore. The rearing of steelhead trout in hatcheries ... ability to reproduce in the wild, a new Oregon ... the wisdom of historic hatchery practices. The research, ... for the first time that the reproductive success of ...
... America (ESA) is proud to announce its selection of ... Selection as an ESA Fellow acknowledges outstanding contributions in ... who have have participated actively in ESA affairs and ... will be recognized during the ESA Annual Meeting, which ...
... worldwide and rank as number one in terms ... a recent ECNP commissioned report has demonstrated (Wittchen ... greatest decrement in health compared with the common ... (Moussavi et al., 2007) followed by addictive disorders ...
Cached Biology News:Salmonid hatcheries cause 'stunning' loss of reproduction 2Salmonid hatcheries cause 'stunning' loss of reproduction 3Entomological Society of America recognizes 2007 fellows and honorary members 2Entomological Society of America recognizes 2007 fellows and honorary members 320th ECNP Congress 2007, Oct. 13-17, Vienna, Austria 220th ECNP Congress 2007, Oct. 13-17, Vienna, Austria 320th ECNP Congress 2007, Oct. 13-17, Vienna, Austria 4